Provectus Pharmaceuticals is focused on developing advanced therapies designed to target and destroy the deadliest cancer as well as developing groundbreaking biotechnologies to augment vaccine production and detect viruses. The company is currently conducting clinical trials on their two proprietary drugs, Provecta and Xantryl.
Provectra is unique from other cancer treatments by concentrating on toxic levels of tissue while avoiding healthy tissue consequently making it safer and more effective than conventional therapies such as chemotherapy and radiation. The drug is targeting melanoma and focal tumors of the breast, liver and prostate, which together account for more than 520,000 new cases in the United States each year and are among the most difficult cancers to treat using conventional therapies.
Xantryl is primarily focused on treating psoriasis. Current treatments for the disease carry disadvantages such as potentially developing skin cancer, suppressing the immune system, and requiring repeated injections. Xantryl separates itself from these disadvantages by specifically targeting only diseased tissue and confining the effects of light activation to only areas of skin affected by psoriasis.
In addition to its core pharmaceutical work, the company has also developed a number of intellectual properties and technologies in the fields of medical devices and biotechnologies. Provectus has shown itself to be an emerging player in the growing pharmaceutical industry has great potential to improve health care worldwide by using breakthrough products that are both economical and easy to manufacture.
Let us hear your thoughts: Provectus Pharmaceuticals, Inc. Message Board